Quest Diagnostics (DGX) announced that Adrienne Brott has been named senior vice president and chief quality and regulatory affairs officer. Brott is responsible for leading the company’s quality and regulatory strategy to enhance quality adherence and control as well as compliance with U.S. and global regulations and industry standards for laboratory diagnostic information services. Prior to joining Quest, Brott was senior vice president, quality and regulatory for the acute care therapies division of Getinge, a global medical technology company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics upgraded to Outperform from Market Perform at Leerink
- Quest Diagnostics price target raised to $177 from $174 at Mizuho
- Mainz Biomed forms agreement with Quest Diagnostics
- Pfizer provides FY25 outlook, McCormick in talks for Sauer Brands: Morning Buzz
- Tesla upgraded, MongoDB initiated: Wall Street’s top analyst calls